Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Index Funds median (375 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 02 Jan 2013 – 20 Aug 2026. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one. Nifty 50 history starts 18 Jul 2016, so that benchmark is not plotted over this window — pick a shorter range to see it.
View as table
| Date | LIC MF BSE Sensex Index Fund |
|---|---|
| 02 Jan 2013 | ₹100.00 |
| 21 Feb 2014 | ₹105.74 |
| 12 Apr 2015 | ₹147.54 |
| 31 May 2016 | ₹136.60 |
| 19 Jul 2017 | ₹164.43 |
| 07 Sep 2018 | ₹197.45 |
| 27 Oct 2019 | ₹202.38 |
| 15 Dec 2020 | ₹241.27 |
| 03 Feb 2022 | ₹308.42 |
| 25 Mar 2023 | ₹304.56 |
| 12 May 2024 | ₹388.93 |
| 01 Jul 2025 | ₹452.68 |
| 20 Aug 2026 | ₹421.86 |
| Metric | LIC · Direct NAV ₹156.49 Very High risk ★★☆☆☆ | Category median Index Funds · 375 funds |
|---|---|---|
| -4.90% | +5.66% | |
| +6.76% | +8.82% | |
| +7.82% | +9.15% | |
| +11.31% | +11.72% | |
| +11.14% | +7.67% | |
| +5.69% | — | |
| +12.35% | +12.67% | |
| +12.87% | +13.64% | |
| +12.47% | +12.84% | |
| Risk | ||
| 13.19% | 13.97% | |
| 0.02 | 0.24 | |
| 0.03 | 0.36 | |
| -37.53% | -16.12% | |
| Nifty 50 | — | |
| -1.03% | +0.84% | |
| 0.98 | 1.00 | |
| 97.7% | 102.2% | |
| 104.0% | 97.2% | |
| 0.66% | 0.36% | |
| ₹90.05Cr | ₹177.09Cr | |
| 0.25% | — | |
| None | — | |
| ₹200 | — | |
| ₹5.00K | — | |
| 27% | 35% | |
| Sumit Bhatnagar · 2.9y | — | |
| 02 Jan 2013 | — | |
| 30 | — | |
| 64.0% | — | |
| 0.7% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.